Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metabolic considerations in hypertension.

M L Tuck1

  • 1Department of Medicine, Los Angeles School of Medicine, University of California.

American Journal of Hypertension
|December 1, 1990
PubMed
Summary

Hypertension, obesity, and diabetes share common metabolic and genetic factors. Calcium channel blockers and ACE inhibitors are recommended first-line treatments for obese and diabetic hypertensive patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Familial obesity, sympathetic activation and blood pressure level.

Blood pressure·2002
Same author

Differences in mechanisms between weight loss-sensitive and -resistant blood pressure reduction in obese subjects.

Hypertension research : official journal of the Japanese Society of Hypertension·2001
Same author

Long-term fructose feeding impairs vascular relaxation in rat mesenteric arteries.

American journal of hypertension·2001
Same author

Selective aspects of the insulin resistance syndrome.

Current opinion in nephrology and hypertension·2001
Same author

Weight reduction and pharmacologic treatment in obese hypertensives.

American journal of hypertension·2001
Same author

Inhibitors of arachidonic acid metabolism have variable effects on calcium signaling pathways.

American journal of hypertension·2001

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Hypertension Research

Background:

  • Hypertension frequently co-occurs with obesity and diabetes mellitus, indicating shared underlying genetic and environmental factors.
  • These conditions contribute to metabolic and cardiovascular derangements, accelerating atherosclerosis and increasing morbidity and mortality.
  • Abnormalities in blood pressure regulation, including the renin-angiotensin system and sympathetic nervous system, are observed in diabetes.

Purpose of the Study:

  • To explore the interconnectedness of hypertension, obesity, and diabetes mellitus.
  • To identify common metabolic and vascular characteristics linking these conditions.
  • To guide optimal pharmacotherapy selection for hypertensive individuals with obesity and diabetes.

Main Methods:

  • Review of existing literature on the pathophysiology of hypertension, obesity, and diabetes.
  • Analysis of metabolic and vascular adaptations associated with these conditions.
  • Evaluation of medication classes for efficacy and metabolic impact in this patient population.

Main Results:

  • Insulin resistance is proposed as a unifying link between hypertension, obesity, and diabetes.
  • Early signs of sodium retention and cardiovascular hyperreactivity in diabetes may precede hypertension.
  • Obesity is associated with altered sympathetic activity, sodium metabolism, and hemodynamics, predisposing to hypertension.

Conclusions:

  • Calcium channel blockers and angiotensin-converting enzyme inhibitors are effective first-line treatments for obese and diabetic hypertensives due to their favorable metabolic profiles.
  • Diuretics and beta-blockers may not be ideal initial choices due to potential metabolic complications in this patient group.
  • Understanding the metabolic interplay is crucial for selecting medications that avoid adverse effects in patients with co-existing hypertension, obesity, and diabetes.

Related Experiment Videos